To improve the ability of CAR-T cells to infiltrate tumor environments, researchers have modified GPC3-CAR-T cells to express interleukin 7 (IL-7) and chemokine CCL19, resulting in positive outcomes in experimental studies (32). Here, IL7 is linked to neoplasm.